 | • レポートコード：MRC2Q12-19286 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、オファツムマブのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 オファツムマブのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 オファツムマブの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 オファツムマブのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのオファツムマブの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のオファツムマブの売上および2028年までの予測に焦点を当てています。 オファツムマブのグローバル主要企業には、BOC Sciences、GlaxoSmithKline(GSK)、Lonza Group、Novartis International、TargetMol Chemicals、Hubei Kele Fine Chemical、Jiangxi Ruiweier Biotechnology、Nantong Feiyu Biological Technology、Shanghai Biochempartner、Shanghai Macklin Biochemical、Shanghai Yifei Biotechnology、Tianmen Hengchang Chemical、Wuhan Topule Biopharmaceutical、Wuhan Wogeda Biotechnology、Wuhan Yingnuo Pharmaceutical Technologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 オファツムマブ市場は、タイプとアプリケーションによって区分されます。世界のオファツムマブ市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 特許、ジェネリック 【アプリケーション別セグメント】 化学、医薬品 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - オファツムマブ製品概要 - タイプ別市場（特許、ジェネリック） - アプリケーション別市場（化学、医薬品） - 調査の目的 ・エグゼクティブサマリー - 世界のオファツムマブ販売量予測2017-2028 - 世界のオファツムマブ売上予測2017-2028 - オファツムマブの地域別販売量 - オファツムマブの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別オファツムマブ販売量 - 主要メーカー別オファツムマブ売上 - 主要メーカー別オファツムマブ価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（特許、ジェネリック） - オファツムマブのタイプ別販売量 - オファツムマブのタイプ別売上 - オファツムマブのタイプ別価格 ・アプリケーション別市場規模（化学、医薬品） - オファツムマブのアプリケーション別販売量 - オファツムマブのアプリケーション別売上 - オファツムマブのアプリケーション別価格 ・北米市場 - 北米のオファツムマブ市場規模（タイプ別、アプリケーション別） - 主要国別のオファツムマブ市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのオファツムマブ市場規模（タイプ別、アプリケーション別） - 主要国別のオファツムマブ市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のオファツムマブ市場規模（タイプ別、アプリケーション別） - 主要国別のオファツムマブ市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のオファツムマブ市場規模（タイプ別、アプリケーション別） - 主要国別のオファツムマブ市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのオファツムマブ市場規模（タイプ別、アプリケーション別） - 主要国別のオファツムマブ市場規模（トルコ、サウジアラビア） ・企業情報 BOC Sciences、GlaxoSmithKline(GSK)、Lonza Group、Novartis International、TargetMol Chemicals、Hubei Kele Fine Chemical、Jiangxi Ruiweier Biotechnology、Nantong Feiyu Biological Technology、Shanghai Biochempartner、Shanghai Macklin Biochemical、Shanghai Yifei Biotechnology、Tianmen Hengchang Chemical、Wuhan Topule Biopharmaceutical、Wuhan Wogeda Biotechnology、Wuhan Yingnuo Pharmaceutical Technology ・産業チェーン及び販売チャネル分析 - オファツムマブの産業チェーン分析 - オファツムマブの原材料 - オファツムマブの生産プロセス - オファツムマブの販売及びマーケティング - オファツムマブの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - オファツムマブの産業動向 - オファツムマブのマーケットドライバー - オファツムマブの課題 - オファツムマブの阻害要因 ・主な調査結果 |
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
Market Analysis and Insights: Global Ofatumumab Market
Due to the COVID-19 pandemic, the global Ofatumumab market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Patent accounting for % of the Ofatumumab global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Chemical segment is altered to an % CAGR throughout this forecast period.
China Ofatumumab market size is valued at US$ million in 2021, while the US and Europe Ofatumumab are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ofatumumab landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Ofatumumab include BOC Sciences, GlaxoSmithKline(GSK), Lonza Group, Novartis International, TargetMol Chemicals, Hubei Kele Fine Chemical, Jiangxi Ruiweier Biotechnology, Nantong Feiyu Biological Technology and Shanghai Biochempartner, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Ofatumumab Scope and Segment
Ofatumumab market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Ofatumumab market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Patent
Generic
Segment by Application
Chemical
Pharmaceutical
By Company
BOC Sciences
GlaxoSmithKline(GSK)
Lonza Group
Novartis International
TargetMol Chemicals
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Nantong Feiyu Biological Technology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Yifei Biotechnology
Tianmen Hengchang Chemical
Wuhan Topule Biopharmaceutical
Wuhan Wogeda Biotechnology
Wuhan Yingnuo Pharmaceutical Technology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Ofatumumab Product Introduction
1.2 Market by Type
1.2.1 Global Ofatumumab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Patent
1.2.3 Generic
1.3 Market by Application
1.3.1 Global Ofatumumab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Chemical
1.3.3 Pharmaceutical
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Ofatumumab Sales Estimates and Forecasts 2017-2028
2.2 Global Ofatumumab Revenue Estimates and Forecasts 2017-2028
2.3 Global Ofatumumab Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Ofatumumab Sales by Region
2.4.1 Global Ofatumumab Sales by Region (2017-2022)
2.4.2 Global Sales Ofatumumab by Region (2023-2028)
2.5 Global Ofatumumab Revenue by Region
2.5.1 Global Ofatumumab Revenue by Region (2017-2022)
2.5.2 Global Ofatumumab Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Ofatumumab Sales by Manufacturers
3.1.1 Global Top Ofatumumab Manufacturers by Sales (2017-2022)
3.1.2 Global Ofatumumab Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Ofatumumab in 2021
3.2 Global Ofatumumab Revenue by Manufacturers
3.2.1 Global Ofatumumab Revenue by Manufacturers (2017-2022)
3.2.2 Global Ofatumumab Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Ofatumumab Revenue in 2021
3.3 Global Ofatumumab Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Ofatumumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Ofatumumab Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Ofatumumab Sales by Type
4.1.1 Global Ofatumumab Historical Sales by Type (2017-2022)
4.1.2 Global Ofatumumab Forecasted Sales by Type (2023-2028)
4.1.3 Global Ofatumumab Sales Market Share by Type (2017-2028)
4.2 Global Ofatumumab Revenue by Type
4.2.1 Global Ofatumumab Historical Revenue by Type (2017-2022)
4.2.2 Global Ofatumumab Forecasted Revenue by Type (2023-2028)
4.2.3 Global Ofatumumab Revenue Market Share by Type (2017-2028)
4.3 Global Ofatumumab Price by Type
4.3.1 Global Ofatumumab Price by Type (2017-2022)
4.3.2 Global Ofatumumab Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Ofatumumab Sales by Application
5.1.1 Global Ofatumumab Historical Sales by Application (2017-2022)
5.1.2 Global Ofatumumab Forecasted Sales by Application (2023-2028)
5.1.3 Global Ofatumumab Sales Market Share by Application (2017-2028)
5.2 Global Ofatumumab Revenue by Application
5.2.1 Global Ofatumumab Historical Revenue by Application (2017-2022)
5.2.2 Global Ofatumumab Forecasted Revenue by Application (2023-2028)
5.2.3 Global Ofatumumab Revenue Market Share by Application (2017-2028)
5.3 Global Ofatumumab Price by Application
5.3.1 Global Ofatumumab Price by Application (2017-2022)
5.3.2 Global Ofatumumab Price Forecast by Application (2023-2028)
6 North America
6.1 North America Ofatumumab Market Size by Type
6.1.1 North America Ofatumumab Sales by Type (2017-2028)
6.1.2 North America Ofatumumab Revenue by Type (2017-2028)
6.2 North America Ofatumumab Market Size by Application
6.2.1 North America Ofatumumab Sales by Application (2017-2028)
6.2.2 North America Ofatumumab Revenue by Application (2017-2028)
6.3 North America Ofatumumab Market Size by Country
6.3.1 North America Ofatumumab Sales by Country (2017-2028)
6.3.2 North America Ofatumumab Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Ofatumumab Market Size by Type
7.1.1 Europe Ofatumumab Sales by Type (2017-2028)
7.1.2 Europe Ofatumumab Revenue by Type (2017-2028)
7.2 Europe Ofatumumab Market Size by Application
7.2.1 Europe Ofatumumab Sales by Application (2017-2028)
7.2.2 Europe Ofatumumab Revenue by Application (2017-2028)
7.3 Europe Ofatumumab Market Size by Country
7.3.1 Europe Ofatumumab Sales by Country (2017-2028)
7.3.2 Europe Ofatumumab Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Ofatumumab Market Size by Type
8.1.1 Asia Pacific Ofatumumab Sales by Type (2017-2028)
8.1.2 Asia Pacific Ofatumumab Revenue by Type (2017-2028)
8.2 Asia Pacific Ofatumumab Market Size by Application
8.2.1 Asia Pacific Ofatumumab Sales by Application (2017-2028)
8.2.2 Asia Pacific Ofatumumab Revenue by Application (2017-2028)
8.3 Asia Pacific Ofatumumab Market Size by Region
8.3.1 Asia Pacific Ofatumumab Sales by Region (2017-2028)
8.3.2 Asia Pacific Ofatumumab Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Ofatumumab Market Size by Type
9.1.1 Latin America Ofatumumab Sales by Type (2017-2028)
9.1.2 Latin America Ofatumumab Revenue by Type (2017-2028)
9.2 Latin America Ofatumumab Market Size by Application
9.2.1 Latin America Ofatumumab Sales by Application (2017-2028)
9.2.2 Latin America Ofatumumab Revenue by Application (2017-2028)
9.3 Latin America Ofatumumab Market Size by Country
9.3.1 Latin America Ofatumumab Sales by Country (2017-2028)
9.3.2 Latin America Ofatumumab Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Ofatumumab Market Size by Type
10.1.1 Middle East and Africa Ofatumumab Sales by Type (2017-2028)
10.1.2 Middle East and Africa Ofatumumab Revenue by Type (2017-2028)
10.2 Middle East and Africa Ofatumumab Market Size by Application
10.2.1 Middle East and Africa Ofatumumab Sales by Application (2017-2028)
10.2.2 Middle East and Africa Ofatumumab Revenue by Application (2017-2028)
10.3 Middle East and Africa Ofatumumab Market Size by Country
10.3.1 Middle East and Africa Ofatumumab Sales by Country (2017-2028)
10.3.2 Middle East and Africa Ofatumumab Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 BOC Sciences
11.1.1 BOC Sciences Corporation Information
11.1.2 BOC Sciences Overview
11.1.3 BOC Sciences Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 BOC Sciences Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 BOC Sciences Recent Developments
11.2 GlaxoSmithKline(GSK)
11.2.1 GlaxoSmithKline(GSK) Corporation Information
11.2.2 GlaxoSmithKline(GSK) Overview
11.2.3 GlaxoSmithKline(GSK) Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline(GSK) Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline(GSK) Recent Developments
11.3 Lonza Group
11.3.1 Lonza Group Corporation Information
11.3.2 Lonza Group Overview
11.3.3 Lonza Group Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Lonza Group Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Lonza Group Recent Developments
11.4 Novartis International
11.4.1 Novartis International Corporation Information
11.4.2 Novartis International Overview
11.4.3 Novartis International Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis International Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis International Recent Developments
11.5 TargetMol Chemicals
11.5.1 TargetMol Chemicals Corporation Information
11.5.2 TargetMol Chemicals Overview
11.5.3 TargetMol Chemicals Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 TargetMol Chemicals Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 TargetMol Chemicals Recent Developments
11.6 Hubei Kele Fine Chemical
11.6.1 Hubei Kele Fine Chemical Corporation Information
11.6.2 Hubei Kele Fine Chemical Overview
11.6.3 Hubei Kele Fine Chemical Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Hubei Kele Fine Chemical Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Hubei Kele Fine Chemical Recent Developments
11.7 Jiangxi Ruiweier Biotechnology
11.7.1 Jiangxi Ruiweier Biotechnology Corporation Information
11.7.2 Jiangxi Ruiweier Biotechnology Overview
11.7.3 Jiangxi Ruiweier Biotechnology Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Jiangxi Ruiweier Biotechnology Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Jiangxi Ruiweier Biotechnology Recent Developments
11.8 Nantong Feiyu Biological Technology
11.8.1 Nantong Feiyu Biological Technology Corporation Information
11.8.2 Nantong Feiyu Biological Technology Overview
11.8.3 Nantong Feiyu Biological Technology Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Nantong Feiyu Biological Technology Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Nantong Feiyu Biological Technology Recent Developments
11.9 Shanghai Biochempartner
11.9.1 Shanghai Biochempartner Corporation Information
11.9.2 Shanghai Biochempartner Overview
11.9.3 Shanghai Biochempartner Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Shanghai Biochempartner Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Shanghai Biochempartner Recent Developments
11.10 Shanghai Macklin Biochemical
11.10.1 Shanghai Macklin Biochemical Corporation Information
11.10.2 Shanghai Macklin Biochemical Overview
11.10.3 Shanghai Macklin Biochemical Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shanghai Macklin Biochemical Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai Macklin Biochemical Recent Developments
11.11 Shanghai Yifei Biotechnology
11.11.1 Shanghai Yifei Biotechnology Corporation Information
11.11.2 Shanghai Yifei Biotechnology Overview
11.11.3 Shanghai Yifei Biotechnology Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Shanghai Yifei Biotechnology Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Shanghai Yifei Biotechnology Recent Developments
11.12 Tianmen Hengchang Chemical
11.12.1 Tianmen Hengchang Chemical Corporation Information
11.12.2 Tianmen Hengchang Chemical Overview
11.12.3 Tianmen Hengchang Chemical Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Tianmen Hengchang Chemical Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Tianmen Hengchang Chemical Recent Developments
11.13 Wuhan Topule Biopharmaceutical
11.13.1 Wuhan Topule Biopharmaceutical Corporation Information
11.13.2 Wuhan Topule Biopharmaceutical Overview
11.13.3 Wuhan Topule Biopharmaceutical Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Wuhan Topule Biopharmaceutical Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Wuhan Topule Biopharmaceutical Recent Developments
11.14 Wuhan Wogeda Biotechnology
11.14.1 Wuhan Wogeda Biotechnology Corporation Information
11.14.2 Wuhan Wogeda Biotechnology Overview
11.14.3 Wuhan Wogeda Biotechnology Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Wuhan Wogeda Biotechnology Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Wuhan Wogeda Biotechnology Recent Developments
11.15 Wuhan Yingnuo Pharmaceutical Technology
11.15.1 Wuhan Yingnuo Pharmaceutical Technology Corporation Information
11.15.2 Wuhan Yingnuo Pharmaceutical Technology Overview
11.15.3 Wuhan Yingnuo Pharmaceutical Technology Ofatumumab Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Wuhan Yingnuo Pharmaceutical Technology Ofatumumab Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Wuhan Yingnuo Pharmaceutical Technology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Ofatumumab Industry Chain Analysis
12.2 Ofatumumab Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Ofatumumab Production Mode & Process
12.4 Ofatumumab Sales and Marketing
12.4.1 Ofatumumab Sales Channels
12.4.2 Ofatumumab Distributors
12.5 Ofatumumab Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Ofatumumab Industry Trends
13.2 Ofatumumab Market Drivers
13.3 Ofatumumab Market Challenges
13.4 Ofatumumab Market Restraints
14 Key Findings in The Global Ofatumumab Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer